Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-665 mimic
- Development stage
- Unknown
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intraperitoneal, Intradermal
01
Overview
miR-665 mimic is an experimental research compound consisting of a small, chemically synthesized double-stranded RNA molecule designed to mimic the activity of the endogenous microRNA miR-665 (hsa-miR-665). It is used in preclinical and academic research settings to study the functional role of miR-665 by upregulating miRNA activity in cell and animal models. The compound has no single developing company, brand name, or approved clinical indication, and is synthesized by various reagent suppliers (such as MedChemExpress and GenePharma) for experimental use. Studies have investigated the miR-665 mimic in several disease contexts, including sevoflurane anesthesia-induced cognitive dysfunction, myocardial ischemia-reperfusion injury, lung squamous cell carcinoma, breast cancer metastasis, and cardiac hypertrophy.
- Other names
- hsa-miR-665 mimichsa-miR665 mimichsa-miR 665 mimicmicroRNA-665 mimicmicroRNA665 mimicmicroRNA 665 mimicrno-miR-665 mimicrno-miR665 mimicrno-miR 665 mimic
02
Targets
CNR2 (Cannabinoid receptor type 2)CD34 (Hematopoietic progenitor cell antigen CD34)LASP1 (LIM and SH3 domain protein 1)NR4A3 (Nuclear receptor subfamily 4 group A member 3)E3 ligase (E3 ubiquitin ligases)AK1 (Adenylate kinase 1)B7-H3CB (Cannabinoid receptors)CRIM1 (Cysteine-rich motor neuron 1 protein)IGF2 (Insulin-like growth factor 2)MYC (MYC proto-oncogene protein)PTPRB (Vascular endothelial-protein tyrosine phosphatase)
Beyond the preview
Go deeper on miR-665 mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-665 mimic.